INTRODUCTION {#sec1-1}
============

Human parechoviruses (HPeVs) belong to the Picornaviridae family and were previously classified as echovirus 22 and echovirus 23 \[Hyypiä et al., [1992](#bib13){ref-type="ref"}; Oberste et al., [1999](#bib19){ref-type="ref"}\]. Fourteen HPeV genotypes have been described worldwide \[Ito et al., [2004](#bib14){ref-type="ref"}; Boivin et al., [2005](#bib8){ref-type="ref"}; Benschop et al., [2006a](#bib4){ref-type="ref"}, [2008](#bib6){ref-type="ref"}; Al‐Sunaidi et al., [2007](#bib2){ref-type="ref"}; Watanabe et al., [2007](#bib25){ref-type="ref"}; Drexler et al., [2009](#bib10){ref-type="ref"}; Li et al., [2009](#bib17){ref-type="ref"}; Calvert et al., [2010](#bib9){ref-type="ref"}; Kim et al., [2010](#bib15){ref-type="ref"}\]. Clinical manifestations of HPeV infection including gastrointestinal, respiratory, and neurologic syndrome. HPeV1 and 2 have been associated with mild respiratory and gastrointestinal infections \[Abed and Boivin, [2006](#bib1){ref-type="ref"}; Harvala et al., [2008](#bib12){ref-type="ref"}; Harvala and Simmonds, [2009](#bib11){ref-type="ref"}\] and, in rare cases, with necrotizing enterocolitis \[Birenbaum et al., [1997](#bib7){ref-type="ref"}\]. HPeV3 has been associated with sepsis‐like illness, severe neurologic manifestations \[Ito et al., [2004](#bib14){ref-type="ref"}; Boivin et al., [2005](#bib8){ref-type="ref"}\], and infant death \[Levorson et al., [2009](#bib16){ref-type="ref"}; Sedmak et al., [2010](#bib22){ref-type="ref"}\]. Although HPeV genotypes 4--14 were identified in a number of different countries, their clinical role remains to be clarified \[Benschop et al., [2006a](#bib4){ref-type="ref"}, [2008](#bib6){ref-type="ref"}; Al‐Sunaidi et al., [2007](#bib2){ref-type="ref"}; Watanabe et al., [2007](#bib25){ref-type="ref"}; Drexler et al., [2009](#bib10){ref-type="ref"}; Li et al., [2009](#bib17){ref-type="ref"}; Calvert et al., [2010](#bib9){ref-type="ref"}; Kim et al., [2010](#bib15){ref-type="ref"}\]. On the other hand, HPeVs are not included usually in diagnostic panels, thus, the HPeV infection rate might be underestimated.

The aims of present study were to investigate the prevalence of HPeV infections in hospitalized patients in the Northern Italy, analyze the clinical characteristics of HPeV infections, and characterize the circulating strains by phylogenetic analysis.

MATERIALS AND METHODS {#sec1-2}
=====================

In the period October 2008--2010 were tested retrospectively by HPeV‐specific real‐time RT‐PCR \[Nix et al., [2008](#bib18){ref-type="ref"}\]: (i) 5,283 respiratory samples (nasal swab, nasopharyngeal aspirates, or bronchoalveolar lavage) from 3,525 patients (1,938 pediatric and 1,587 adult) with respiratory syndromes; (ii) 353 cerebrospinal fluid (CSF) from 340 patients with neurologic syndromes (80 pediatric and 260 adult); and (iii) multiple specimens (three CSF, three plasma, five respiratory, and three stool sample) from five neonates with sepsis‐like illness. Patients were stratified with respiratory syndrome according to Baumgarte et al. \[[2008](#bib3){ref-type="ref"}\] comparing patients \<2 years of age with respect to patients \>2 years of age.

All respiratory samples were tested prospectively with a diagnostic panel of 17 respiratory viruses \[Piralla et al., [2009](#bib21){ref-type="ref"}\]. CSF samples were tested prospectively for herpes simplex, varicella zoster, cytomegalovirus, polyomavirus, and enterovirus. Virologic and clinical data for HPeV‐positive patients were retrieved from medical records.

Genotyping was performed by sequencing amplification products of the VP3/VP1 region \[Harvala et al., [2008](#bib12){ref-type="ref"}\] using the BigDye Terminator cycle sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA) and the ABI Prism 3100 DNA sequencer (Applied Biosystems). Sequences were assembled with Sequencer software (4.6 version, Gene Code Corp., Ann Arbor, MI) and multiple sequence alignment was conducted using MEGA version 5.0 \[Tamura et al., [2011](#bib23){ref-type="ref"}\]. Nucleotide sequences from the VP3/VP1 region have been submitted to GenBank under accession numbers JN112318‐JN112338.

RESULTS {#sec1-3}
=======

Fourteen out of 3,525 (0.4%) patients with respiratory syndromes and five out of five patients with sepsis‐like illness were positive for HPeV (Table [I](#tbl1){ref-type="table"}). None of the patients with neurologic syndromes was positive for HPeV. Of the 14 HPeV‐positive patients with respiratory syndromes 6 (42.9%) had lower respiratory tract infections, while 8 (57.1%) had upper respiratory tract infections. In two premature patients (\#11, and \#13, born at 25 and 29 weeks, respectively) with sequential respiratory samples HPeV‐RNA persisted for up to 25 days (Table [I](#tbl1){ref-type="table"}). The number of patients \<2 years of age (n = 831) was comparable with that of patients \>2 years of age (n = 1,107). Considering the detection rate of respiratory syndrome caused by HPeV only in patients \<2 years the rate increased to 1.6% (13/831) with respect to 0.4% of total rate.

###### 

Clinical Manifestation of HPeV Infections

  Patient no.   Sex/age (years)   Date sample collection (month/year)   Positive clinical samples   Days follow‐up   Symptoms                            Others signs or symptoms                                                           Underlying disease           HPeV typing   Coinfecting virus
  ------------- ----------------- ------------------------------------- --------------------------- ---------------- ----------------------------------- ---------------------------------------------------------------------------------- ---------------------------- ------------- -------------------
  1             M/14 mos          10/2008                               NPA                                          Pharyngitis, cough, pneumonia       Leukocytosis                                                                                                    HPeV1         HRV
  2             M/11 mos          11/2008                               NPA                                          Fever, cough, dyspnea               CRP: 1.7 mg/dl                                                                                                  HPeV1         HRV
  3             M/1               11/2008                               NPA                                          Rhinorrhea, cough                   Leukocytosis                                                                                                    HPeV1         hCoV‐OC43
  4             F/3               11/2008                               NPA                                          Fever, pharyngitis                  Leucosytosis, CRP: 7.99 mg/dl otalgy, fever convulsion                                                          HPeV6         hCoV‐OC43
  5             M/1               11/2008                               NPA                                          Rhinorrhea, cough                   Otalgy, CRP: 2,75 mg/dl, previous athmatic episode                                                              HPeV1         
  6             M/30              12/2008                               NPA                                          Rhinorrhea                                                                                                             Lung transplant (2005)       HPeV3         HRV
  7             F/29 days         07/2009                               CSF                                          Fever, sepsis‐like illness                                                                                                                          HPeV3         
  8             M/1               08/2009                               NPA                                          Fever, cough, wheezing, pneumonia   Leukocytosis                                                                                                    HPeV3         
  9             M/6 mos           11/2009                               NS                                           Rhinorrhea                                                                                                                                          HPeV1         
  10            F/13 mos          11/2009                               NS                                           Rhinorrhea                                                                                                                                          HPeV1         
  11            F/2 mos           12/2009                               NS                          0                Cough                                                                                                                  Premature (25 weeks), CPAP   HPeV1         HRV
                                                                        NS                          11               Cough                                                                                                                                                             
                                                                        NS                          19               Cough                                                                                                                                                             
                                                                        NS                          26                                                                                                                                                                                 
  12            F/50 days         12/2009                               NPA                                          Rhinorrhea, cough, diarrhea                                                                                                                         HPeV1         HRV
  13            F/30 days         12/2009                               NPA                         0                Rhinorrhea, cough, pneumonia                                                                                           Premature (29 weeks)         HPeV1         HRV
                                                                        NPA                         16                                                                                                                                      Bronchopolmunary displasy                  
                                                                        NPA                         29                                                                                                                                                                                 
  14            F/17 mos          04/2010                               NS                                           Fever, wheezing, dyspnea            Leukocytosis, saturation O~2~: 90%. CRP: 5.35 mg/dl, previous asthmatic episodes                                HPeV1         HRV
  15            F/1 mos           07/2010                               CSF, NS, Plasma                              Fever, sepsis‐like illness          Diarrhea, otitis                                                                                                HPeV3         
  16            M/2               09/2010                               NS                                           Fever, cough, cough, dyspnea        Saturation O~2~: 96%, previous asthmatic episodes                                                               HPeV1         HRV
  17            M/14 days         09/2010                               Plasma                                       Sepsis‐like illness, encephalitis                                                                                                                   HPeV3         
  18            F/11 days         10/2010                               CSF, NPA, stool                              Sepsis‐like illness                                                                                                                                 HPeV3         
  19            M/17 days         10/2010                               Plasma, PS                                   Sepsis‐like illness                                                                                                                                 HPeV3         

NPA, nasopharyngeal aspirate; CSF, cerebrospinal fluid; NS, nasal swab; PS, pharyngeal swab; CRP, C reactive protein; HPeV, human parechovirus; HRV, human rhinovirus; hCoV, human coronavirus; mo, month; NA, not available; CPAP, continuous positive airway pressure.
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The patients with sepsis‐like illness were younger (median age, 17 days) with respect to the patients with respiratory infections (median age, 365 days; *P* \< 0.01). Among the patients with sepsis‐like illness, HPeV was detected in different clinical specimens in three patients (\#15, \#18, and \#19, Table [I](#tbl1){ref-type="table"}). Despite neurologic involvement, in two other patients (\#17 and \#19) CSF samples were not available and HPeV was detected in plasma samples. HPeV3 infection was community acquired in four patients with sepsis‐like illness (\#7, \#15, \#17, and \#19), while in one patient (\#18) nosocomial infection was observed. All patients recovered from the infection.

HPeV‐positive patients were identified during the entire study period, 6 (31.6%) in 2008, 7 (36.8%) in 2009, and 6 (31.6%) in 2010. HPeV infections peaked during the fall season with 14/19 (73.7%) positive patients, followed by 5/19 (26.3%) in summer and 1/19 (5.3%) in spring. Ten of 14 (71.4%) HPeV‐positive patients with respiratory syndromes were co‐infected with other respiratory viruses (eight with rhinovirus and two with coronavirus OC43). In five patients with sepsis‐like illness no coinfecting viruses were found.

Eleven of 19 (57.9%) patients were infected with an HPeV1 virus strain, 7/19 (36.8%) patients were infected with an HPeV3 virus strain, and the remaining patient was infected with an HPeV6 virus strain (Fig. [1](#fig1){ref-type="fig"}).

![Phylogenetic tree constructed with VP3/VP1 (nt 2,165--2,457 with respect to HPeV1 strain Harris; accession number S45208) nucleotide sequences from reference strains (in bold) and Italian HPeV strains (n = 21) from 19 patients. Phylogenetic analysis was inferred by using the maximum likelihood method based on the Tamura 3‐parameter model as an evolutionary model. A discrete gamma distribution was used to model evolutionary rate differences among sites. The tree was drawn to scale, with branch lengths measured in the number of substitutions per site.](JMV-84-686-g001){#fig1}

Nucleotide identity among HPeV1 sequence strains ranged from 84.3% to 100%, and in HPeV3 sequences from 92.9% to 100%. HPeV1 sequence strains from patients \#11, \#12, and \#13 were closely related (100% identity) and were indentified in patients hospitalized in the same pediatric unit (Table [I](#tbl1){ref-type="table"}). The HPeV3 sequences amplified from different clinical samples of patient \#18 were identical to each other. HPeV3 sequence from patient \#6 was amplified from a NPA sample collected in 2008 and was divergent from sequences circulating in 2009 and 2010.

DISCUSSION {#sec1-4}
==========

In agreement with previous data a low prevalence of HPeV in respiratory samples was observed \[Harvala et al., [2008](#bib12){ref-type="ref"}\] and detection was restricted to the patients \<2 years of age. The frequent association of HPeV infections with other respiratory viruses may indicate a less pathogenic role for HPeV compared to the other viruses infecting the respiratory tract. The low number of single infections in our series did not allow to draw major conclusions on the role of HPeV respiratory syndromes. Few data have been published on the duration of virus shedding. In our series, HPeV infection persisted for 25 days in two neonates.

HPeV3 has been shown recently to be an important cause of severe infections in very young children including sepsis‐like illness and encephalitis \[Ito et al., [2004](#bib14){ref-type="ref"}; Boivin et al., [2005](#bib8){ref-type="ref"}; Levorson et al., [2009](#bib16){ref-type="ref"}\]. In our series, five patients \<1 month of age with sepsis‐like illness were infected with HPeV3. In three of these patients, multiple samples (plasma, stool, CSF, or respiratory sample) were HPeV‐positive. These findings support the hypothesis of a disseminated infection caused by HPeV3 \[Piňeiro et al., [2010](#bib20){ref-type="ref"}; Sedmak et al., [2010](#bib22){ref-type="ref"}\]. The detection of HPeV in different biologic specimens from patients with sepsis‐like illness may help to clarify the extent of the infection. On the other hand, none of patients with neurologic syndromes in the absence of sepsis‐like illness was positive for HPeV, thus suggesting that HPeV neurotropism might be limited to specific clinical conditions. In keeping with other reports \[Benschop et al., [2006b](#bib5){ref-type="ref"}, [2008](#bib6){ref-type="ref"}; van der Sanden et al., [2008](#bib24){ref-type="ref"}\], the majority of HPeV infections in our study were observed in the fall season.

Despite the limitations of this retrospective study and the need for prospective studies to better define the clinical impact of HPeV infection, some conclusions can be drawn: (i) HPeV does not circulate with high frequency, (ii) the role of HPeV in the respiratory syndrome indicated a bystander phenomena; (iii) HPeV may be associated with severe clinical syndromes in a minority of newborns, and (iv) detection of HPeVs in different clinical samples should always be considered in newborns with sepsis‐like illness.
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